Rapid Onset Action of Salbutamol Versus Formoterol
Information source: All India Institute of Medical Sciences, New Delhi
ClinicalTrials.gov processed this data on August 23, 2015 Link to the current ClinicalTrials.gov record.
Condition(s) targeted: Bronchial Asthma
Intervention: salbutamol (Drug); Formoterol (Drug)
Phase: Phase 4
Status: Recruiting
Sponsored by: All India Institute of Medical Sciences, New Delhi Overall contact: S.K Kabra, Dr, Phone: 9868397540
Summary
The hypothesis of this study is that the onset of rapid bronchodilatory effect of inhaled
Formoterol (12 microgram) is comparable to that of inhaled salbutamol (200 microgram) i. e.,
the difference in mean forced expiratory volume in 1 second (FEV1) between the 2 groups at
1, 5, 10, 30 and 60 minutes will be less than 10% in children between 5-15 years with mild
acute exacerbation of asthma.
Clinical Details
Official title: Comparing Rapid Bronchodilatory Effect of Formoterol and Salbutamol in Children Between 5-15 Years With Mild to Moderate Acute Exacerbation of Asthma- A Double Blind Randomized Controlled Trial
Study design: Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Caregiver, Investigator), Primary Purpose: Treatment
Primary outcome: Difference in mean FEV1 between the two groups at 1, 5, 10, 30, 60 minutes
Secondary outcome: Difference in average clinical asthma score between two groupsAdverse effects like tremors, vomiting, palpitation, etc, in two groups Number of patients requiring hospitalization in two groups at end of study period in two groups
Detailed description:
It is desirable to have a single MDI that can be used as both LABA and SABA. There are few
studies involving few children on use of formoterol that shows rapid bronchodilatation in
children with asthma and no study that used it as rescue drug in children with acute
exacerbation of asthma. The purpose of the present study is to evaluate whether the rapid
bronchodilatory effect of formoterol is similar to that of salbutamol in children of 5-15
years with mild exacerbation of asthma.
Children will receive either salbutamol or formoterol by MDI. Participants will be explained
about the study, spirometry and inhalation of medicine with MDI and spacer. Children will
receive two puffs (100 microgram each of salbutamol) or Formoterol 2 puffs (6µg /puff) by
MDI and spacer. Each child will be explained about the inhalation technique by using a MDI
of placebo. After shaking the MDI it will be attached to spacer (700ml volume) and actuated.
Child will be asked to take 5 tidal breaths. Another puff will be given by similar method.
Eligibility
Minimum age: 5 Years.
Maximum age: 15 Years.
Gender(s): Both.
Criteria:
Inclusion Criteria:
1. Children aged 5-15 years of either sex seeking treatment with mild exacerbation of
asthma in pediatric chest clinic or Pediatric OPD
2. Mild exacerbation will be defined as:
- children presenting with increase in symptoms (cough, wheeze, breathlessness)
for less than 7 days duration
- no chest indrawing
- no difficulty in speech
- clinical asthma score (or pulmonary index score-annexure 1) between 6-9
Exclusion Criteria:
1. Children with life threatening asthma detected by presence of any of the following:
- severe chest indrawing
- cyanosis
- irregular respiration
- altered sensorium
2. Children with other chronic respiratory conditions like tuberculosis, cystic fibrosis
or other acute illness that would complicate current treatment and response for
asthma
3. If child has taken salbutamol in last 6 hours or if he is on long acting beta
agonists (formoterol or salmeterol)
4. Child not able to perform spirometry
5. Parents refusing to give consent
Locations and Contacts
S.K Kabra, Dr, Phone: 9868397540
AIIMS, New Delhi 110029, India; Recruiting Jenish Rajma, Principal Investigator
Additional Information
Starting date: January 2009
Last updated: May 12, 2009
|